Bioventus Inc Cl A (BVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 137,069 | 119,059 | 125,834 | 128,662 | 140,331 |
| Cost of Goods | 47,946 | 45,140 | 51,645 | 44,127 | 43,677 |
| Gross Profit | 89,123 | 73,919 | 74,189 | 84,535 | 96,654 |
| Operating Expenses | 83,319 | 166,117 | 90,471 | 211,501 | 100,639 |
| Operating Income | 6,750 | -92,058 | -15,637 | -126,839 | -3,308 |
| Interest Expense | 10,587 | 9,694 | 7,389 | 3,604 | 2,578 |
| Other Income | -513 | 1,588 | -9,414 | -115 | -604 |
| Pre-tax Income | -4,350 | -100,164 | -32,440 | -130,558 | -6,490 |
| Income Tax | 381 | -146 | -10,963 | -29,523 | 1,244 |
| Net Income Continuous | -4,731 | -100,018 | -21,477 | -101,035 | -7,734 |
| Net Income Discontinuous | N/A | -74,429 | -23,396 | -44,663 | -280 |
| Minority Interests | -1,050 | -35,297 | -12,943 | -37,453 | -762 |
| Net Income | $-3,681 | $-139,150 | $-31,930 | $-108,245 | $-7,252 |
| EPS Basic Total Ops | -0.06 | -2.24 | -0.53 | -1.76 | -0.11 |
| EPS Basic Continuous Ops | -0.06 | -1.28 | -0.23 | -1.18 | -0.11 |
| EPS Basic Discontinuous Ops | N/A | -0.96 | -0.30 | -0.58 | 0.00 |
| EPS Diluted Total Ops | -0.06 | -2.24 | -0.53 | -1.76 | -0.11 |
| EPS Diluted Continuous Ops | -0.06 | -1.28 | -0.23 | -1.18 | -0.11 |
| EPS Diluted Discontinuous Ops | N/A | -0.96 | -0.30 | -0.58 | 0.00 |
| EBITDA(a) | $21,350 | $-75,585 | $1,305 | $-113,246 | $9,076 |